BC
KRTX

Bridgefront Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bridgefront Capital’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,463
Closed -$287K – 624
2022
Q4 		$287K Buy
+1,463
New +$314K 0.2% 211

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's KRTX Position: Q1 2023 in Review

Bridgefront Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 1,463 shares — an estimated $287K sold.

Bridgefront Capital first reported a position in KRTX in Q4 2022 and held it in 1 quarter. The position peaked at $287K in Q4 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

  • Bridgefront Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bridgefront Capital sold 1,463 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $287K.
  • Bridgefront Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Bridgefront Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $287K in Q4 2022.
  • 246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Bridgefront Capital's 13F filing for Q1 2023, filed 15 May 2023.